L-Cin A Tablet is a combination pharmaceutical formulation containing Levofloxacin 500 mg and Ambroxol 75 mg, designed for the treatment of respiratory tract infections. Levofloxacin, a broad-spectrum fluoroquinolone antibiotic, acts by inhibiting bacterial DNA gyrase and topoisomerase IV, thereby preventing bacterial replication and transcription, making it effective against a wide range of Gram-positive and Gram-negative pathogens. Ambroxol serves as a mucolytic agent that enhances the clearance of mucus by stimulating surfactant production and improving ciliary activity in the respiratory tract. This dual-action formulation is particularly beneficial in managing acute and chronic bronchitis, pneumonia, sinusitis, and other lower respiratory tract infections where bacterial infection is accompanied by excessive mucus production. The combination facilitates symptomatic relief by reducing bacterial load and promoting expectoration, thereby improving airway patency and respiratory function. L-Cin A Tablet should be administered as prescribed by a healthcare professional, considering patient-specific factors such as renal function and potential drug interactions. It is contraindicated in individuals with known hypersensitivity to fluoroquinolones or Ambroxol. Common adverse effects may include gastrointestinal disturbances, headache, and dizziness. Proper adherence to the prescribed dosage regimen is essential to minimize resistance development and ensure therapeutic efficacy.